Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Pasireotide-pegvisomant combo induces disease control in treatment-resistant acromegaly

10 Nov 2019

Combined treatment with pasireotide and pegvisomant has been shown to control disease in tumours with low somatostatin receptor (SSTR) subtype 2 expression, resistant to conventional somatostatin analogues (SSAs; alone or combined with pegvisomant) and to new-generation SSAs alone (pasireotide), reports a recent study.

“Our data have reinforced the importance of personalized treatment of patients with acromegaly according to the clinical, biochemical, molecular and morphological disease markers,” the authors said.

This study described six patients who were successfully treated with a combination therapy of pasireotide and pegvisomant. Participants were then compared to a control group of patients resistant to conventional SSAs, whose disease was controlled with other treatment, such as pasireotide (as monotherapy) or pegvisomant (as monotherapy of combined with conventional SSAs).

Acromegaly in all six patients was controlled using the combination treatment with pasireotide and pegvisomant after failure of all other therapies. Giant and invasive pituitary adenomas (at both the cavernous sinus and other structures) were found in these six patients compared with the 49 patients in the control group.

Those receiving the combined treatment with pasireotide and pegvisomant had higher growth hormone levels, more elevated Ki-67 expression, greater SSTR subtype 5 expression and lower SSTR subtype 2 expression at the diagnosis of acromegaly as compared with those in the control group. However, this finding was not statistically significant.

“The treatment of acromegaly resistant to first- and second-line therapies can be extremely challenging,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.